Cefpodoxime Proxetil

Summary

Cefpodoxime Proxetil (CHEMBL1201016) is an approved small-molecule prodrug; indicated across 2 conditions including otitis media and osteomyelitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 6
• Chemistry: 557.6 Da · C21H27N5O9S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201016
Name	Cefpodoxime Proxetil
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	6526396
ChEBI	CHEBI:3505
Molecular formula	C21H27N5O9S2
Molecular weight	557.6
InChIKey	LTINZAODLRIQIX-FBXRGJNPSA-N

SMILES: CC(C)OC(=O)OC(C)OC(=O)C1=C(CS[C@H]2N1C(=O)[C@H]2NC(=O)/C(=N\OC)/C3=CSC(=N3)N)COC

IUPAC name: 1-propan-2-yloxycarbonyloxyethyl (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

ChEBI definition: The 1-[(isopropoxycarbonyl)oxy]ethyl (proxetil) ester prodrug of cefpodoxime. After swallowing, hydrolysis of the ester group occurs in the intestinal epithelium, to release active cefpodoxime in the bloodstream. It is used to treat acute otitis media, pharyngitis, and sinusitis.

Pharmacological roles (ChEBI): prodrug, antibacterial drug.

Also known as: Banan, Cefodox, Cefpodoxime proxetil, CS-807, NSC-759161, Otreon, Podomexef, Simplicef, U-76252, Vantin, SID49681553, Cefpodoxime proxetyl

Patent coverage: 2,285 distinct patent families (8,216 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Streptokinase A, Prostaglandin G/H synthase 1, 3’,5’-cyclic-AMP phosphodiesterase 4D, Bile salt export pump.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 4 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P10520	6.1	EC50	797	nM	CHEMBL_ACT_4925547

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
otitis media	4	MONDO:0005441	EFO:0004992

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE1	2
Not specified	2
PHASE4	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05977868	PHASE4	TERMINATED	Comparing Oral Versus Parenteral Antimicrobial Therapy
NCT06406114	PHASE2	RECRUITING	Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
NCT00143533	PHASE1	COMPLETED	Prevention of Diarrhea in Patients Taking IV Irinotecan for Relapsed or Difficult to Treat Pediatric Solid Tumors
NCT03491748	PHASE1	COMPLETED	A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK, the Measure of How the Human Body Processes a Substance) of ETX0282 When Administered Orally to Healthy Participants
NCT00194532	Not specified	COMPLETED	Cefpodoxime vs Ciprofloxacin for Acute Cystitis
NCT03098485	Not specified	COMPLETED	Healthy Patients & Effect of Antibiotics

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).